SGLT-2抑制剂与GLP-1受体激动剂在2型糖尿病中的心肾结局真实世界比较
主要终点为肾衰竭/死亡复合终点,SGLT-2i组风险更低(HR 0.87,95%CI 0.85–0.89),肾脏特异性成分和全因死亡风险也较低,而复合心血管结局两组大致相当。
要点
- SGLT-2i较GLP-1 RA降低肾衰竭/死亡复合终点风险(HR 0.87)。
- SGLT-2i降低肾衰竭、透析或移植风险(HR 0.74)及全因死亡(HR 0.90)。
- 复合心血管结局两组大致相当(HR 0.98,95%CI 0.97–1.00)。
核心结论
- 在2型糖尿病成人中,启动SGLT-2i与较低的肾衰竭相关结局和全因死亡风险相关,心血管结局与GLP-1 RA大致相当。
主要发现
- SGLT-2i组肾衰竭/死亡复合终点风险低于GLP-1 RA组(HR 0.87,95%CI 0.85–0.89)。
- SGLT-2i组肾衰竭、透析或肾移植风险更低(HR 0.74,95%CI 0.71–0.78)。
- SGLT-2i组全因死亡风险更低(HR 0.90,95%CI 0.88–0.93)。
- 复合心血管结局两组大致相当(HR 0.98,95%CI 0.97–1.00)。
临床怎么用
- 对于2型糖尿病成人,选择SGLT-2i或GLP-1 RA时可考虑肾脏和死亡结局的差异以个体化治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABSTRACT Aims To compare cardiorenal outcomes, mortality and safety between sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1 RA) in adults with Type 2 diabetes (T2D). Materials and Methods We conducted a retrospective, new-user cohort study using the TriNetX global federated health research network. We identified 249 237 propensity score-matched pairs (498 474 total patients) who initiated SGLT-2i or GLP-1 RA between 2018 and 2023. The primary outcome was a kidney failure/death composite, defined as kidney failure, dialysis, kidney transplantation or all-cause mortality. Secondary outcomes included composite cardiovascular events, mortality and safety profiles. Results SGLT-2i initiation was associated with a lower risk of the kidney failure/death composite compared with GLP-1 RA (HR: 0.87, 95% CI: 0.85–0.89). For the kidney-specific component, SGLT-2i initiation was associated with a lower risk of kidney failure, dialysis or kidney transplantation (HR: 0.74, 95% CI: 0.71–0.78), while all-cause mortality was also lower (HR: 0.90, 95% CI: 0.88–0.93). The composite cardiovascular outcome (myocardial infarction, stroke, acute heart failure, cardiogenic shock, cardiac arrest or death) was broadly comparable between groups (HR: 0.98, 95% CI: 0.97–1.00). Conclusions SGLT-2i initiation was associated with lower risks of kidney failure-related outcomes and all-cause mortality compared with GLP-1 RA initiation, while cardiovascular outcomes were broadly comparable. These findings may inform individualized treatment selection in adults with T2D.
引用
- Diabetes, Obesity and Metabolism:Real‐World Comparison of Cardiorenal Outcomes With SGLT‐2 Inhibitors Versus GLP‐1 Receptor Agonists in Type 2 Diabetes
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。